SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217282 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024. Verfasst von Natisha R Field und 3 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia. Electronic …. Hauptthemen laut MEDLINE: DNA Helicases, Transcription Factors, Nuclear Proteins, Chromatin Assembly and Disassembly. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Genetic mutations and epigenetic modifications affecting multiple cancer-related genes occur synergistically to drive tumorigenesis. Across a wide spectrum of cancers, pathogenic changes have been identified in members of the SWItch/Sucrose Non-Fermentable complex including its two catalytic subunits, SMARCA4 and SMARCA2. During cancer development, it is not uncommon to lose the function of either SMARCA4 or SMARCA2, however, loss of both together has been reported to be synthetic lethal and therefore unexpected. Co-deficiency of SMARCA4 and SMARCA2 occurs as a pathognomonic feature of the early-onset ovarian cancer Small-cell carcinoma of the ovary, hypercalcemic type. The loss of both catalytic subunits is also described in other rare undifferentiated neoplasms including Thoracic SMARCA4-deficient undifferentiated tumors, Malignant rhabdoid tumors and dedifferentiated or undifferentiated carcinomas, predominantly of lung, gastrointestinal, and endometrial origin. This review provides the first extensive characterization of cancers with concurrent SMARCA4 and SMARCA2 loss through the discussion of shared clinical and molecular features. Further, we discuss the mechanisms triggering the loss of catalytic activity, the cellular processes that are dysfunctional as a consequence, and finally, current therapeutic candidates which may selectively target these cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia. Electronic address: Natisha.Field@student.uts.edu.au.
- Translational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
- Cancer Biology, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Förderung
- National Health and Medical Research Council
Zitieren
APA
Field, N. R., Dickson, K. A., Nassif, N. T., & Marsh, D. J. (2024). SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217282
Vancouver
Field NR, Dickson KA, Nassif NT, Marsh DJ. SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217282
BibTeX
@article{Field2024,
author = {Field, Natisha R and Dickson, Kristie-Ann and Nassif, Najah T and Marsh, Deborah J},
title = {SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217282}
}
EUVIMED